» Articles » PMID: 31262973

Protective Effects of Oxymatrine Against DSS-induced Acute Intestinal Inflammation in Mice Via Blocking the RhoA/ROCK Signaling Pathway

Overview
Journal Biosci Rep
Specialty Cell Biology
Date 2019 Jul 3
PMID 31262973
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Oxymatrine (OMT) is an important quinoxaline alkaloid that has a wide range of pharmacological effects and has been shown to alleviate ulcerative colitis due to its profound anti-inflammatory effects. The RhoA/ROCK (Rho kinase) signaling pathway has been shown to be related to the pathogenesis of several autoimmune diseases; however, the specific mechanisms of RhoA/ROCK signaling in inflammatory bowel disease (IBD) remain elusive. Therefore, we sought to determine whether OMT could ameliorate acute intestinal inflammation by targeting the RhoA/ROCK signaling pathway. The potential therapeutic effect of OMT on acute intestinal inflammation and its impact on the RhoA/ROCK signaling pathway were assessed in six groups of mice treated with low, medium and high doses of OMT (25, 50 and 100 mg/kg, respectively), and an inhibitor of ROCK, Y-27632, as a positive control, after initiating dextran sodium sulfate (DSS)-induced acute intestinal inflammation. The model group and normal group were injected intraperitoneally with equal doses of PBS. Our results showed that OMT treatment could protect the integrity of the epithelial barrier, relieve oxidative stress, inhibit the expression of inflammatory mediators and pro-inflammatory cytokines, restrain the differentiation of Th17 cells and promote the differentiation of Treg cells via inhibition of the RhoA/ROCK pathway, thus providing therapeutic benefits for ulcerative colitis (UC). Therefore, inhibiting the RhoA/ROCK pathway might be a new approach that can be used in UC therapy, which deserves to be investigated further.

Citing Articles

Comparative Efficacy of Plant Extracts and Probiotics on Growth and Gut Health in Chickens with Necrotic Enteritis.

Zhang R, Yang J, Wang Q, Hu D, Zhao Q, Zhu S Animals (Basel). 2024; 14(22).

PMID: 39595364 PMC: 11591468. DOI: 10.3390/ani14223312.


Homocysteine Promotes Intestinal Inflammation in Colitis Mice Through the PGE2/STAT3 Signaling Pathway.

Shao A, Zhao Q, Chen M Dig Dis Sci. 2024; 69(10):3742-3752.

PMID: 39141200 PMC: 11489288. DOI: 10.1007/s10620-024-08588-2.


An updated review of the pharmacological effects and potential mechanisms of hederagenin and its derivatives.

Zhang H, Li Y, Liu Y Front Pharmacol. 2024; 15:1374264.

PMID: 38962311 PMC: 11220241. DOI: 10.3389/fphar.2024.1374264.


Oxymatrine Attenuates Ulcerative Colitis through Inhibiting Pyroptosis Mediated by the NLRP3 Inflammasome.

Sun J, Wang S, Zhao Z, Lu J, Zhang Y, An W Molecules. 2024; 29(12).

PMID: 38930963 PMC: 11206389. DOI: 10.3390/molecules29122897.


HOXD10 regulates intestinal permeability and inhibits inflammation of dextran sulfate sodium-induced ulcerative colitis through the inactivation of the Rho/ROCK/MMPs axis.

Xu J, Lin N Open Med (Wars). 2024; 19(1):20230844.

PMID: 38756247 PMC: 11097047. DOI: 10.1515/med-2023-0844.


References
1.
Anwar K, Fazal F, Malik A, Rahman A . RhoA/Rho-associated kinase pathway selectively regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via activation of I kappa B kinase beta and phosphorylation of RelA/p65. J Immunol. 2004; 173(11):6965-72. DOI: 10.4049/jimmunol.173.11.6965. View

2.
Horowitz S, Binion D, Nelson V, Kanaa Y, Javadi P, Lazarova Z . Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2007; 292(5):G1323-36. DOI: 10.1152/ajpgi.00499.2006. View

3.
Del Re D, Miyamoto S, Brown J . RhoA/Rho kinase up-regulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis. J Biol Chem. 2007; 282(11):8069-78. DOI: 10.1074/jbc.M604298200. View

4.
Rodriguez P, Sahay S, Olabisi O, Whitehead I . ROCK I-mediated activation of NF-kappaB by RhoB. Cell Signal. 2007; 19(11):2361-9. PMC: 2084080. DOI: 10.1016/j.cellsig.2007.07.021. View

5.
Rogler G . Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol. 2010; 24(2):157-65. DOI: 10.1016/j.bpg.2009.10.011. View